featured
Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence After Stopping Imatinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence After Stopping Imatinib First-Line in Chronic Phase CML Patients
Clin. Cancer Res 2019 Jul 10;[EPub Ahead of Print], FE Nicolini, S Dulucq, L Boureau, P Cony-Makhoul, A Charbonnier, M Escoffre-Barbe, F Rigal-Huguet, V Coiteux, B Varet, V Dubruille, P Lenain, P Rousselot, D Rea, A Guerci-Bresler, L Legros, J Liu, M Gardembas, JC Ianotto, P Turlure, H Johnson-Ansah, J Martiniuc, H Jardel, B Joly, P Zunic, T Henni, B Villemagne, MG Berger, E Cayssials, F Guilhot, F Larosa, J Guilhot, G Etienne, FX MahonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.